EE701 Cost-Effectiveness Analysis of Polatuzumab Vedotin Combined with Chemoimmunotherapy in Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in China
Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.966
https://www.valueinhealthjournal.com/article/S1098-3015(23)04096-2/fulltext
Section Title :
Section Order :
10459
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04096-2&doi=10.1016/j.jval.2023.09.966